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Kidneys are one of the most frequently transplanted human organs. Immunosuppressive agents may prevent or reverse most
acute rejection episodes; however, the graft may still succumb to chronic rejection. The immunological response involved in the
chronic rejection process depends on both innate and adaptive immune response. T lymphocytes have a pivotal role in chronic
rejection in adaptive immune response. Meanwhile, we aim to present a general overview on the state-of-the-art knowledge of the
strategies used for manipulating the lymphocyte activation mechanisms involved in allografts, with emphasis on T-lymphocyte
costimulatory and coinhibitory molecules of the B7-CD28 superfamily. A deeper understanding of the structure and function
of these molecules improves both the knowledge of the immune system itself and their potential action as rejection inducers or
tolerancepromoters.Inthiscontext,thecentralroleplayedbyCD28family,especiallytherelationshipbetweenCD28andCTLA-4,
becomes an interesting target for the development of immune-based therapies aiming to increase the survival rate of allografts and
to decrease autoimmune phenomena. Good results obtained by the recent development of abatacept and belatacept with potential
clinical use aroused better expectations concerning the outcome of transplanted patients.
1.Introduction
Kidneys are one of the most frequently transplanted human
organs, with approximately 10,000 kidney transplants being
performed annually in the United States [1]. Regarding
absolute numbers of kidney transplantations, Brazil ranks
second amongallcountries, aftertheUnited States and ranks
ninth per million inhabitants [2]. The Brazilian Uniﬁed
National Health System (Sistema ´ Unico de Sa´ ude—SUS)p a y s
for more than 95% of the transplants performed in the
country [2], and it provides the necessary posttransplant
medication and follow-up care, representing a growing
demand upon public resources [3]. It may be the largest
public transplant program worldwide [4].
Recipients of successful transplants have higher quality
of life, which is directly linked to the continuous normal
graft function [5]. Over the past two decades, signiﬁcant
progress has been achieved in graft rates and patient survival
rates after kidney transplantation [6]. Some studies show
that the half-life of deceased and living related allografts has
improved to 13.8 and 21.6 years, respectively [7], and that
thereismorethan95%ofpatientsurvivalrateandmorethan
91% of organ survival rate in one year [1].
Allograftrejectionoccursbecausetherecipient’simmune
system recognizes the donor’s tissue as foreign and attacks
the graft. Immunosuppressive agents may prevent or reverse
most acute rejection episodes. However, even though these
agents prevent acute rejection, the graft may still succumb to
a more insidious type of chronic rejection characterized by
replacement ﬁbrosis of the graft parenchyma developing for
over months or years [8].
As immunosuppressive agents have become more eﬀec-
tive at controlling acute rejection, chronic rejection has
emerged as one of the major problems in clinical practice.2 Journal of Transplantation
This process leads to an inexorable loss of kidneys at the rate
o fa p p r o x i m a t e l y5 %t o7 %p e ry e a r[ 9, 10].
Analysis of sequential renal transplant biopsies suggests
thatchronicrejectionrepresentscumulativeandincremental
damage to the graft due to time-dependent immunologic
and nonimmunologic causes, whereby chronic allograft
dysfunction is the chief cause of kidney transplant failure
[11, 12]. Most grafts are lost because of a continuous process
characterized by interstitial ﬁbrosis, tubular atrophy, and
severe atherosclerosis [13, 14].
According to Banﬀ classiﬁcation, rejection can be medi-
ated by both antibodies and T lymphocytes, and it may
be acute or chronic [12]. C4d complement fragment was
the antibody-mediated rejection marker [12]. Nevertheless,
the low sensitivity of that marker was discussed in the last
meeting in 2011 [15], as there may be an antibody-mediated
rejectionandleukocyteactivationwithantibodyFcreceptors
without activation of complement cascade, case in which
there is no C4d deposition [15]. There might be changes in
Banﬀ classiﬁcation concerning antibody-mediated rejection
in the next meeting in 2013 in Brazil [15].
A chronic active T-cell-mediated rejection has arterial
intimal ﬁbrosis with mononuclear cell inﬁltration in ﬁbrosis,
formation of neo-intima, called chronic allograft arteriopa-
thy [16]. In that case, lymphocytes seem to play a key role in
the immune response of the graft, leading to tissue damages
[17].
2. Immunology of ChronicRejection
The immunological response involved in the chronic rejec-
tion process depends on both innate and adaptive immune
response. Evidence has been drawing attention to the
involvement of innate mechanisms, such as the complement
systemandtheNKcells,inchronicrejection[18].Inadaptive
immunity,antigenpresentingcells(APCs)playanimportant
role in directing the response of T lymphocytes, either by
direct response (donor APC) or indirect response (recipient
APC) [19]. It is assumed that the stimulation of T-cells
through direct response tends to decrease over time as donor
APCs are replaced by host APCs. Thus, the predominant
immune response causing chronic rejection occurs through
an indirect pathway. B lymphocytes have a major role in
the development of chronic rejection, whether it may be
acting as APCs, or as a source of cytokines, or by producing
alloantibodies. The latter have a great potential of activation
ofthecomplement systemandthebinding mechanism atthe
Fc region in phagocytes [12]. On the other hand, regulatory
Blymphocytes (alsoknown as Bregs)may have an important
part in promoting graft tolerance maintenance, both directly
through regulatory cytokine production, such as IL-10, or by
contributing to an increase in Tregs [20–25].
Studies in pigs suggested that vascular changes observed
inchronicrejectionsaremorelikelytooccurwhendisparities
are observed in class I antigens rather than class II anti-
gens, indicating that CD8+ T-cells are implicated in lesion
development. In rat models, however, there is some pieces
of evidence that both CD4+ and CD8+ cells are capable of
causing lesions and that disparities in both class I or class II
antigen presentation are crucial to induce chronic rejection
[26]. Studies in mice have shown that class I disparities are
enough to induce cardiac allograft pathology. That could be
explained by the expression of MHC class II on the vascular
endothelium of transplanted mice with vascular lesions [27].
Because MHC class II is not constitutively expressed by
vascular endothelial cells of mice, indirect recognition of
donor class II transferred from passenger leukocytes may
be responsible for inducing an inﬂammatory response that
leads to subsequent upregulation of class II on the vascular
endothelium of the donor. Adoptive transfer studies in mice
have revealed that in the absence of T-cells alloantibodies are
able to induce vascular alterations that are typical of chronic
rejection [28]. Nonetheless, another study showed that in
the absence of B cells, T-cells do induce lesion development,
but with less tendency to progress to a ﬁnal stage of ﬁbrosis
[29]. Moreover, evenin theabsenceofT-cellsothercellssuch
as NK cells could induce lesions in cardiac allografts [30].
Hence, it seems that various immunological mechanisms
are capable of inducing characteristic lesions observed in
chronic rejections, and that T-cells alone are not essential
for their induction. So far, the existence of a single mediator
that could be commonly involved in all these pathways is
still unclear. Even though, cytokine IFN-γ seems to play a
vital role in lesion development in many diﬀerent chronic
rejection models [27, 31]. Vasculopathy in STAT4-deﬁcient
mice, which are nonresponders to IL-12 stimulation and are
incapable of generating Th1 responses, is less intense than
the vasculopathy observed in wild-type mice [32]. On the
other hand, the anti-inﬂammatory cytokine TGF-β would
be important to attenuate lesion size, but because of its
proﬁbrotic role, TGF-β is highly expressed in vascular lesions
caused by chronic rejections [33].
It is noteworthy that the deﬁnition of the immune
response mechanisms involved in chronic rejections is still
unclear, as the key molecules involved in the immunopatho-
genesisofthisentityarestillunknown.Meanwhile,weaimto
present a general overview on the state-of-the-art knowledge
of the strategies used for manipulating the lymphocyte
activation mechanisms involved in allograft rejection, with
emphasis on T lymphocyte costimulatory molecules. First,
we will focus on the key molecules involved in the basic
co-stimulatory and co-inhibitory processes of T-cell biology.
Afterwards, we will discuss some of the most important
experimental and clinical studies that shed some light on the
increasing survival of solid transplanted organs, particularly
kidney transplant.
3. T-Cell ImmuneResponse: ATwo-Signal
Hypothesis andMore
T lymphocytes are considered to be the key cells involved
in host-cell immune response, mainly due to their ability
to be activated in an antigen-speciﬁc manner and to
potentiate components of both innate and adaptive immune
responses. It has been demonstrated that only antigen-
speciﬁc activation—mediated by TCR—was not enough to
cause lymphocyte activation and, also, when it occurredJournal of Transplantation 3
alone it led to cell anergy and peripheral tolerance [34].
In addition, great importance has been given to the co-
stimulatory and co-inhibitory signaling molecules which
together with TCR signaling form a model initially called
the Two-signal hypothesis [35]. Later studies showed that
lymphocyte activation, besides being a process mediated
by two signals (antigenic recognition and costimulation),
depends on the coordinated interaction of various molecules
calledcostimulatorsandcoinhibitors,giventhecapacitysuch
molecules have to mediate the stimulation or inhibition of
speciﬁc antigen activation [36–38]. Nowadays it is known
that costimulation of T helper cells is crucial for determining
their phenotype. The diﬀerent subtypes of eﬀector T-cells
are all generated from na¨ ıve T-cells according to the type
and intensity of co-stimulatory signals recognized during
the cell diﬀerentiation process. Furthermore, the action of
eﬀector cells on the periphery, although in a lesser extent,
is still driven by the signals generated from the antigenic
recognition by TCR. Taking these variable functions into
account,itisofgreatinteresttobetterunderstandthebalance
between T-cell costimulation and coinhibition events in
chronic infections [39], tumors [40], autoimmune diseases
[41], asthma [42], and allograft tolerance [43], as it might
represent important therapeutic strategies.
4. B7-CD28 Superfamily
Although the interaction between B7-1 and B7-2 with
CD28 or CTLA-4 is classically considered as the main co-
stimulatory and co-inhibitory stimuli, many other molecules
have been described to act in these processes. Because of
their structural similarities these molecules are placed in
large groups or families, such as B7-CD28 superfamily, TNF-
TNFR superfamily, CD2 superfamily, Integrins superfamily,
and TIM superfamily. This paper will focus on the key
members of the B7-CD28 superfamily, their biology, and the
promising intervention in their signaling pathways, which
allows for the development of new therapeutic strategies
capable of maintaining renal allograft survival for a long
time after implantation in the host. The main members of
the CD28 family and their principal roles are summarized in
Table 1.
5.CD28 andCTLA-4
Traditionally, the relationship between T-lymphocyte cos-
timulation and co-inhibition is demonstrated by CD28/
CTLA-4 duality. Both molecules are expressed on the T-cell
surface and share the same ligands, mainly B7-1 (CD80)
and B7-2 (CD86), constitutively expressed on the cell surface
of APCs and augmented on activated dendritic cells (DCs)
[103]. In spite of their redundancy in the binding to B7-
1 or B7-2, CD28 and CTLA-4 molecules signal antagonist
functions in T lymphocytes [51, 104]: the interaction of
B7-1/B7-2 with CD28 as well as antigen recognition via
TCR both provide a continuous co-stimulatory signal to
activate lymphocytes and induce the expression of anti-
apoptotic genes, for example, Bcl-2 and Bcl-XL [49, 50].
Consequently, this interaction also induces cell survival and
proliferation and IL-2 production, and it potentiates the T-
cell-dependent B-cell activation [51–54]. Nevertheless, the
binding of the same molecules to CTLA-4 induces the
expression of proapoptotic genes as well as the production of
immunoregulatory cytokines, and it also favors restoration
of homeostasis and induction of peripheral tolerance, both
required for the prevention of autoimmune phenomena and
for the survival of transplanted organs [40, 51, 53, 55–58].
Although CD28 and CTLA-4 share the same ligands,
their availability on the cell surface and their binding aﬃnity
to speciﬁc ligands may vary according to the diﬀerentiation
stage of the cell or even according to the cell subtype: na¨ ıve
T-cells express 10 times less CTLA-4 than CD28 on their
surface [105]. After cell activation, the expression of CTLA-
4 increases progressively [55, 106]. For example, CTLA-4 is
constitutively expressed on the cell surface of regulatory T-
cells, and its aﬃnity to CD80 is increased [107, 108].
Studies have shown that the absence of CTLA-4 in
regulatory T-cells leads to a noticeable loss of its suppress-
ing functions, causing uncontrolled lymphoproliferative
response, autoimmune disease, and increased production of
immunoglobulins. This may be due to the fact that CTLA-
4-expressing Tregs reduce CD80 and CD86 expression in
antigen-presenting cells [78, 109]. Mice lacking CD28 or
CD80/CD86 expression are extremely susceptible to infec-
tions [110, 111], while CTLA-4-deﬁcient animals develop
severeimmunopathologiesafewweeksafterbirth[112–114].
This eﬀect might be prevented by administration of CTLA-
4-Ig [115].
6. ICOS
Another co-stimulatory molecule that belongs to the CD28-
superfamily is ICOS [59], whose unique ligand is called
ICOSL [116–118] .T h eI C O Sm o l e c u l ei sac o r e c e p t o r
which is expressed at low levels on na¨ ıve lymphocytes,
but which is upregulated after TCR and CD28 stimulation
[44]. Moreover, ICOS expression has been correlated with
the T-cell diﬀerentiation into Th1, Th2, Th17, Tfh, and
Treg lymphocytes [44–46], but with distinct upregulation
mechanisms for each subpopulation [45, 119]. Among the
main eﬀects of ICOS-ICOSL binding is the induction of
T-cell proliferation with increased IL-2, IL-4, IL-5, IL-10,
IFN-γ,T N F - α, and GM-CSF production [44, 59, 60]. Some
studies performed in vivo showed that the absence of ICOS
makes the animals more susceptible to viral and helminthic
infections, mainly due to a considerable decrease in Th1
and Th2 responses [120]. The lack of ICOS expression
also inhibits the development of autoimmune diseases and
airway inﬂammation [121, 122], but it induces an important
loss of memory T-cell function [123]. Interestingly, ICOS
expression seems to be crucial for the development and
homeostasis of Tregs [61, 62], while deﬁcient mice had some
defects in tolerance induction [124].
7.PD-1
Like CTLA-4, PD-1 molecule is a member of the CD28
superfamily whose functions are related to the inhibition of4 Journal of Transplantation
Table 1: Expression of CD28 family members, ligands, and targeting in transplantation.
Receptor CD28 CTLA-4 ICOS PD-1
Expression Constitutive on
T-cells Induced on T-cells
Induced on Tcells
after TCR and
CD28 stimulation
[44]. Th1, Th2,
Th17, Tfh, and
Treg lymphocytes
[44–46]
Tl y m p h o c y t e s ,B
lymphocytes, monocytes
and NK cells [47, 48]
Ligand CD80 (B7.1);
CD81 (B7.2)
CD80 (B7.1);
CD81 (B7.2)
ICOS-L (CD275,
B7-H2, B7h,
B7RP-1)
PD-L1 (CD274, B7-H1);
PD-L2 (CD273, B7-DC)
Ligand expression
APCs, activated
dendritic cells
(DC) B cells,
T-cells, monocytes
APCs, activated
dendritic cells (DC) B
cells, T-cells,
monocytes
Nonlymphoid cells
(liver, ling, kidney)
APCs, activated
dendritic cells
(DC) B cells,
T-cells, monocytes
Nonlymphoid cells
(liver, lung,
kidney)
DCs, T and B lymphocytes,
mesenchymal stem cells,
mast-cells and other
nonhematopoietic cells
[125, 126]
Major role
Positive
costimulation
expression of
antiapoptotic
genes [49, 50]c e l l
survival,
proliferation, IL-2
production and
potentiates the
T-cell-dependent
activation of B
lymphocytes
[51–54]
Negative
costimulation
Expression of the
proapoptotic genes
Production of
immunoregulatory
cytokines Peripheral
tolerance
[40, 51, 53, 55–58]
Positive
costimulation
induction of T-cell
proliferation,
augmented
cytokine
production
[44, 59, 60]
Generation and
homeostasis of
Treg cells [61, 62]
Negative costimulation
[63, 64]. Inhibitor of cell
proliferation and cytokine
production [65–67].
Peripheral cell tolerance
[68–70]. Suppression
mediated by Treg [71]
Role in Allograft
Rejection
CD28−/−-delayed
graft rejection
[72, 73]C D 2 8
co-stimulatory
blockade—graft
survival [74–77]
↑ number of Treg cells
[78, 79]. Augmented
number of CTLA-4
molecules—↑
tolerance to allografts
[80]C T L A - 4 - I g — ↓
proliferation of
allospeciﬁc T-cells
[81, 82]; prevent the
rejection [83–85]; ↑
graft survival in
human
transplantation
[86–90]
Allograft rejection
[91] ICOS-Ig—↑
graft survival
[64, 92–97]; ↓
kidney transplant
survival [98]
Regulation of alloimmune
responses in animal models
[99–101]. Anti-PD-1
treatment—↑ graft survival
anti-PD-L1 antibodies ↑
rejection process [101].
PD-L1 expression in
transplanted
tissues—tolerance to the
graft [102]
immune responses [63, 64]. Unlike other family members,
PD-1 is expressed over many developmental stages of CD4+
and CD8+ T lymphocytes, B lymphocytes, monocytes, and
NKcells[47,48].Itbindstoatleasttwoligandsdenominated
PD-L1 and PD-L2, which are expressed on a large variety of
cell types, such as DCs, T and B lymphocytes, mesenchymal
stemcells,mast-cells,andothernonhematopoieticcells[125,
126]. PD-1 is a potent inhibitor of cell proliferation and
cytokine production [65–67], being capable of inhibiting T-
cell activation even at low concentrations [127]. In addition,
PD-1 participates in the suppressive processes mediated by
Tregs [71] so it is an important molecule in maintaining
peripheral cell tolerance, which is essential to avoid autoim-
mune reactions and to allow the graft to increase its survival
rate [68–70]. Interestingly, other studies have shown that
PD-L1 and PD-L2 may contribute to the co-stimulatoryJournal of Transplantation 5
signals of T lymphocytes, raising the question of whether
these molecules have ligands other than PD-1 [128–130].
Many other molecules were and still have been found to
play an important role in the co-stimulatory or co-inhibitory
processes that rule T-cell biology. The next section of this
paper is devoted to the role of these molecules both in the
host response to the allografts and in potential interference
strategies in allogeneic transplant models.
8. Role of a Second-Signal on
Allogeneic ImmuneResponse:In Vitro and
In Vivo Approaches
In a recent revision by Vicentini (2008), since the 1970s the
description of the two-signal hypothesis was crucial for lym-
phocytedevelopmentandtheeﬀectorfunction[35],asmany
models have been used to evaluate the diverse strategies used
in the manipulation of the co-stimulatory or co-inhibitory
molecules in animal models. These strategies are crucial for
understanding the role played by these signals in response to
allografts,aswellasforthedevelopmentofnewdrugsaiming
to increase graft survival or to reduce the deleterious eﬀects
of autoimmune reactions, especially by interfering with B7-
1/B7-2 and CD28 pathways [86, 131–137].
9. From Mice to Belatacept
As aforementioned, the interaction of CD28 with B7-1 and
B7-2 molecules is the usual co-stimulatory signal, while the
interaction of CTLA-4 with its receptors provides a stop sig-
nal for T-cell activation stages. Since initial studies, the inter-
ference on these pathways has been deemed a useful strategy
to ﬁght autoimmune reactions and graft rejection or to
upregulate the immune response against chronic infections.
Nevertheless, it is noteworthy that an interference in the
CD28 signaling pathway alone seems to be unable to prove
what preliminary studies suggested: that CD28−/− animals
arestillcapableofrejectingagraft[72],yetafteralongertime
than expected for a wild-type animal, which suggests that
other co-stimulatory pathways might be important for graft
rejection [72, 73]. It is also clear that adult animals whose
CD28co-stimulatorypathwayisblockedobtainbetterresults
regarding graft tolerance and survival rates [81], emphasiz-
ing that knockout animals probably develop other compen-
sation strategies in the absence of CD28 signals. On the other
hand, CTLA-4 expression in experimental models seemed to
b em o r er e l a t e dt ot h en u m b e ra n df u n c t i o no fa l l o s p e c i ﬁ c
T-cells and to the increasing number of Tregs [78, 79]. The
administration of anti-CD45RB antibodies, which increases
the number of CTLA-4 molecules, leads to a temporary
increase in CTLA-4-dependent tolerance to allografts [80].
Essentially, three approaches have been used to interfere
with CD28 signaling pathway and to increase allograft
survival: use of anti-CD28 or anti-B7-1/B7-2 blocking anti-
bodies, the administration of CTLA-4-Ig, a fusion protein of
CTLA-4, and Fc of immunoglobulin (Ig).
Experimental models using anti-CD28 antibodies
showed the longest tolerance time to kidney transplants
[74], reduced donor cell reaction, and a synergistic eﬀect
between these antibodies and rapamycin in GVHD models
[75]. Interestingly, CD28 stimulatory antibodies also
demonstrated to be potential inhibitors of the host response
against allografts, mainly due to an increase in the apoptosis
rateofeﬀectorcells[75–77]. Haspot and colleagues observed
a better response and an increased tolerance to kidney
transplants concerning IDO and iNOS (inducible nitric
oxide synthase) [138]. Conversely, a clinical trial adopting
this strategy showed that the administration of anti-CD28
in six volunteers initiated a systemic inﬂammatory response
[139], probably due to a huge secretion of proinﬂammatory
cytokines by stimulated T-cells [140]. It is noteworthy
to mention that this syndrome has never been found
in experimental models involving nonhuman primates
[75–77].
The administration of anti-B7-1/B7-2 antibodies showed
it is capable to decrease the rejection rate of kidney
transplants in animal models [141, 142] and in preclinical
human studies [143], but despite these good initial results,
this approach has not evolved into clinical trials [144].
Nowadays, the usual strategy is to block the co-
stimulatory pathway through the administration of CTLA-
4-Ig, a fusion protein consisted of the Fc region of immu-
noglobulinGandoftheextracellulardomainofthemolecule
CTLA-4, initially named abatacept [133, 145], that acts as a
competitor in the binding of CD28 to B7-1/B7-2 [108].
Initial studies demonstrated that in vitro addition of
these molecules completely blocked the proliferation of T-
cells against alloantigens [81], induced cell anergy [82], and
decreased the T-cell-dependent antibody response [145].
Studies on experimental models of cardiac transplantation
showed promising results on the use of CTLA-4-Ig by
blocking or even postponing the rejection process [83–85].
In rodent models of transplantation, the administration of
CTLA-4-Ig or anti-CD80 and anti-CD86 antibodies for a
short period of time was able to prevent the rejection of
MHC-mismatched heart, kidney, and pancreas [133, 146–
149], although the same results could not be observed in
skin transplants or in nonhuman primate models, when
only a slight increase in graft tolerance was observed [150–
152].Areasonableexplanationforsuchmodestresultswould
be that avidity of abatacept to B7-2 is weaker than to B7-
1[ 137], and, thus, does not block CD28-B7-2 interaction,
previously described as vital in the initiation of alloimmune
reaction [153]. This binding diﬀerence was crucial to the
need of a second generation of CTLA-4-Ig to be developed,
which was named LEA29Y or belatacept. This new molecule
was obtained from a mutation in two positions (L104E and
A 2 9 Y ) ,w h i c hr e s u l t e di nat e nt i m e ss t r o n g e ra ﬃnity of
belatacept to B7-1 and B7-2 binding than that obtained by
abatacept [137].
AlthoughithadbeenindicatedthatB7-2blockadewould
allow for a more eﬀective induction of tolerance to grafts
than the blockade of B7-1 [154], when both molecules
were simultaneously blocked, however, better results were
achieved [153].
Some recent studies have shown that belatacept has other
actions rather than decreasing the number of eﬀector T-cells6 Journal of Transplantation
or increasing the function of Treg cells [155, 156]. However,
in vitro studies showed that belatacept can lower the number
of na¨ ıve and eﬀector T-cells and that the modiﬁed Fc region
of the molecule is unable to induce either complement-
dependent or antibody-dependent cytotoxicity phenomena
[157].
By evaluating the potential inﬂuence of proinﬂamma-
tory cytokines on belatacept action, Zhao and colleagues
suggested that IL-6 participates in allograft response and
that the modulation of this cytokine production may
increase tolerogenic potential of belatacept administration
[158]. Previously, it has been demonstrated that CTLA-
4-Ig regulates the expression of IDO—Indoleamine 2,3-
dioxygenase—an enzyme that degrades tryptophan and
deactivates T lymphocytes [159]. A recent study in humans
showed an increase in the number of Tregs and CD16+IDO+
cells in belatacept-treated patients when compared with
other patients who received cyclosporine treatment [87]. In
experimental models, it could be noticed that the eﬀect of
belatacept depends on a combined action of IDO and Tregs
[160].
Clinical studies comparing the eﬃcacy of various belat-
acept regimens and cyclosporine treatment—in both cases
the drugs were associated with basiliximab induction therapy
(IL2R blocker), mycophenolate mofetil, and steroids—showed
that after six months of transplant the acute rejection rate
was similar regardless of the chosen drug. Nonetheless, the
group treated with a more intense regimen of belatacept
had better renal function and reduced chronic allograft
nephropathy rate [86, 88, 89]. Furthermore, side eﬀects of
belatacept in comparison with those of cyclosporine or of
other calcineurin inhibitors are less intense with a reduced
number of events such as leukopenia, anemia, edema,
urinary tract infection, hypokalemia, acidosis, diabetes
mellitus, and hypertension [86]. Another study evaluating
1,425 patients also observed better results with belatacept
over cyclosporine administration [161]. However, Rostaing
and colleagues could not observe huge diﬀerences among
groups of patients treated with cyclosporine, belatacept, or
tacrolimus [162].
The combination of rATG, belatacept, and sirolimus
showedbetterinvitroandinvivoresults,withhighersurvival
rate of Treg cells and greater inhibition of alloreactive
eﬀector T-cell response after one year of treatment [90].
Another recent clinical study showed that patients who
received belatacept alone, without an immunosuppressive
drug or short-course tacrolimus immunosuppression, had
better renal function and lower acute rejection rates in
comparison with the patients who received tacrolimus for a
longer period of time [163].
Itisremarkablethatnotableadvanceshavebeenachieved
by recent clinical trials using the aforementioned strate-
gies. Nevertheless, more attention should be drawn to the
real beneﬁts and the potential risks the wide administra-
tion of these drug regimens lead to, especially after the
occurrence of posttransplant lymphoproliferative disorders
(PTLD) in EBV-positive patients treated with belatacept
[164, 165].
10. The Other CD28 Family Members
ICOS-ICOSLPathway. Despitetheclearunderstandingofits
exact role in transplantation, a recent study has suggested
that the ICOS-ICOSL co-stimulatory pathway might be
relevant in the allograft rejection process [91]. Many murine
models suggested that an increased graft survival rate would
be observed after administration of blocking antibodies
directed to ICOS or the administration of ICOS-Ig in hepatic
[92] and cardiac transplants [93] and in GVHD [94, 95].
These strategies also prevented the development of chronic
allograft vasculopathy [96] ,b u tt h e yw e r eu n a b l et op r e v e n t
graft rejection in a model of kidney transplant [98]. This
discrepancy in the results seems to be related to the timing
of ICOS blockade and to the concomitant blockade of the
CD28 pathway. In addition, studies in mice suggested that
earlyadministrationofanti-ICOShasmoremodestresultsin
prolonging graft survival than late administration, when the
suppressive eﬀects of CD8+ T-cells were more pronounced
[61]. Rodent experimental models of cardiac allografts had
an increased graft survival rate when ICOS blockade was
associated with cyclosporine, CTLA-4-Ig, or anti-CD40L
(CD40 receptor, a co-stimulatory member of the TNF-TNFR
family) [64, 96, 97]. Functionally, ICOS blockade suppresses
the activation and the cytokine production of alloreactive T-
cells [96], and it interferes with memory T-cell recruitment
to the allograft [166]. Interestingly, Hodgson and colleagues
observed that the administration of anti-ICOS provides
a better tolerance to xenotransplant, characterized by an
increasing number of inﬁltrating Tregs in the transplanted
tissue [167]. More importantly, though, is the wide distri-
bution of ICOS molecules within the T-cell subpopulations,
having many key roles in the development of eﬀector and
regulatory immune responses [44–46]. Such observation
may limit the clinical use of ICOS-ICOSL inhibitors once the
blockade of this signaling pathway would deplete important
mechanisms involved in graft tolerance.
PD-1-PD-L1/PD-L2 Pathway. The interaction between PD-
1 and its ligands seems to play a pivotal role in the regulation
of alloimmune responses in animal models [99–101], when
the blockade of this interaction leads to rapid allograft
rejection [168]. The administration of anti-PD-1 blocking
antibodies reduces the deleterious eﬀects of GVHD [169].
Interestingly, however, are the conﬂicting results obtained
by the administration of blocking antibodies directed to
other molecules of the PD-1 pathway. While anti-PD-1
treatment increases graft survival rate, the administration
of anti-PD-L1 antibodies accelerates the rejection process
[101]. These results could be explained by the fact that PD-
1 interaction with PD-L1 rather than with PD-L2 is vital
for maintaining graft tolerance [170, 171]. Furthermore, the
eﬀects observed by the blockade of PD-1 interaction with its
ligandsseemtodependontheCD28co-stimulatorypathway
[172]. Additionally, it has been shown that besides PD-1-
PD-L1 interaction, the binding of PD-1 to B7-1 also plays
an important role in the inhibition of alloimmune responses
[173]. Other studies have pointed out an important role ofJournal of Transplantation 7
PD-1 ligands, especially PD-L1, in graft survival in many
transplantmodels.Morerecently,PD-L1expressionintrans-
planted tissues has been implicated in the induction of graft-
host tolerance [102], probably by controlling the deleterious
eﬀects of ischemia and reperfusion injury [174, 175]o rb y
suppressing alloreactive T-cells in kidney transplants [176].
Apart from the aspects regarding rejection physiopathology,
new studies correlate PD-1 expression or some functional
polymorphisms of this molecule with an increased risk of
cytomegalovirus infection in patients undergoing kidney or
liver transplantation [177–181]. Likewise, the determination
of mRNA expression in biological ﬂuids of PD-1 as well as
in other co-stimulatory molecules appears to be a further
strategy capable of predicting acute renal rejection [182–
186].
11.Immunological Barriersto Effective
Costimulation Blockade
Although we have been noticing promising results regarding
blockade strategies of co-stimulator molecules as a therapy
for graft tolerance maintenance in the past years, such
strategy does not always have positive outcomes. A few
individuals are resistant to costimulation blockade-induced
tolerance. Some intrinsic factors of the receptor or factors
related to cells from the donor may hinder the success of
this therapy. Two important situations may have a negative
impact on the success of costimulation blockade: the donor-
reactive T-cell precursor frequency and the resistance of
receptormemoryT-cellstothemechanismsofcostimulation
blockade.
It has been demonstrated for some time that diﬀer-
ent T-lymphocyte subclasses have distinct sensitivities to
costimulation blockade as a tolerance inducer, particularly
CD8 T-cells + graft [187, 188]. Moreover, it has been
demonstrated that the frequency of donor-reactive T-cells
may hinder the interference of costimulation blockade in
the generation of eﬀector T-cells, and that such generated
cells may lead to graft rejection [144]. Important studies by
Ford and colleagues showed that, at a low frequency, donor-
reactive T-cell precursors are susceptible to costimulation
blockade, interfering with the generation of graft rejection
eﬀectorcells. On the other hand, a high donor-reactive T-cell
precursorfrequencyisresistanttotheactionofcostimulation
blockers, which may generate eﬀector cells even in the
presence of blockers [189–191].
Another relevant possibility that may hinder the success
of the therapy with co-stimulator blockers is the previous
occurrence of donor MHC-peptide complexes in the recep-
tor memory T-cells with cross-reactivity. These cells can
be generated by prior transplantation, blood transfusion,
pregnancy, or environmental exposure to pathogens [144,
192]. In fact, many studies have shown that the concomitant
occurrence of some types of infections leads to decreased
graft tolerance [192–197]. Typically, memory cells have less
needofactivationsignalsthanna¨ ıvecells,bothsignalsarising
from antigen and from co-stimulator molecules [198, 199];
hence, they are also resistant to the eﬀects of costimulation
blockade. The right understanding of the role of donor-
reactive T-cell precursors and of memory cells with cross-
reactivity to donor MHC-peptide complexes in the rejection
process, as well as the right understanding of how such
obstacle might be overcome, can improve the success of
costimulation blockade strategies to a greater extent.
12. Concluding Remarks
As described above, co-stimulatory molecules play a piv-
otal role in immune response control. Over the years,
many molecules and surface receptors have been described
as potent controllers of both eﬀector or regulatory T-
lymphocyte development and function. A deeper under-
standing of the structure and function of these molecules
improves both the knowledge of the immune system itself
and also their potential action as rejection inducers or tol-
erance promoters. In this context, the central role played by
CD28 family, especially the relationship between CD28 and
CTLA-4,becomesaninterestingtargettothedevelopmentof
immune-basedtherapiesaimingtoincreaseallograftsurvival
rate and to decrease autoimmune phenomena. Good results
obtained by the recent development of drugs with potential
clinical use aroused better expectations concerning the
outcome of transplanted patients, even though large-scale
studies are still needed to conﬁrm their safety and advantage
over traditional therapies. Furthermore, the manipulation of
the signaling pathway of other members of the CD28 family,
such as ICOS and PD-1, may provide new perspectives for
additional therapies and also for important markers of graft
survival.
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